Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

St Jude Medical’s OptiSense pacing lead receives CE Mark approval

St Jude Medical : 25 June, 2007  (New Product)
St Jude Medical has announced CE Mark approval of its new OptiSense lead, a first of its kind pacing lead designed to offer more accurate sensing in the upper chamber of the heart (right atrium).
The lead, which will be introduced at the Europace 2007 Meeting in Lisbon, Portugal, incorporates a new tip design that increases the device's ability to detect and classify electrical signals in the atrium more accurately by avoiding picking up signals from the heart's lower chambers (ventricles).

This improves the pacemaker's response to sensed signals and the accuracy of device diagnostic reports.

This improved device therapy has now been demonstrated in two completed clinical trials.

The results from the International OptiSense Lead Clinical Study were presented at Europace 2007 by Johannes Sperzel, MD, of the Kerckhoff-Klinik in Bad Nauheim, Germany.

(Results from the US OptiSense Lead Clinical IDE (investigational device exemption) Study were presented in May at the Heart Rhythm Society's Scientific Sessions in Denver, Colorado).

Because the design of the OptiSense lead allows for more accurate detection of impulses from the patient's atrium, the new lead offers physicians more flexibility in programming the device's atrial sensitivity settings while avoiding the sensing of signals from the ventricles.

In the past, physicians sometimes had to program a pacemaker to be less sensitive to avoid the detection of interfering signals.

However, while decreasing the sensitivity settings helps to reduce the interfering signals, it can also reduce the sensing of important signals, like the small signals that can occur during atrial arrhythmias.

By reducing the detection of unwanted signals, the OptiSense lead also may give physicians greater freedom in lead placement options.

With the OptiSense lead, physicians may be able to place leads lower in the atrium - a potentially optimal location for pacing that previously created challenges because of interfering signals from the heart's lower chambers.

'Accurate atrial sensing is especially important when using pacemaker therapy for patients with atrial tachyarrhythmia', said Dr Sperzel.

'In clinical studies of the OptiSense lead, we had greater freedom in lead placement and were able to use higher atrial sensitivity settings to more readily detect even very fine atrial signals'.

The improved sensing performance of the OptiSense lead is a result of compressed spacing between the lead's tip and ring.

The 1.1mm tip-to-ring spacing reduces oversensing of far-field R-wave signals (an electrical signal originating in the lower chamber of the heart and sensed by the lead in the upper chamber of the heart).

Conclusions from the US OptiSense Lead Clinical IDE Study showed:

- The OptiSense lead had no evidence of paced far-field signals in 90.9 percent of patients compared to 40.9 percent of the control patients (p less than 0.0001).

- The OptiSense lead group exhibited a highly statistically significant reduction (p = 0.03) in the percentage of patients with inappropriate mode switching (6.9 percent of OptiSense lead patients versus 25.7 percent of control group patients) as well as a highly statistically significant reduction (p = 0.009) in the percentage of episodes of inappropriate mode switching (three percent versus 49 percent).

Inappropriate mode switching is not desirable because, if it occurs, it can cause a loss of synchrony between the upper and lower chambers of the heart.
In addition to the OptiSense lead, St Jude Medical also presented its newest pacemakers - the Zephyr family of devices - at Europace 2007.

The Zephyr pacemaker is designed to save valuable clinic time by automatically performing all standard follow-up testing before the patient arrives in the clinic.

When a Zephyr device is interrogated during a follow-up visit, the stored diagnostics, trends and measurements from the automatic tests are displayed for evaluation.

Physicians can validate each test by viewing the associated stored electrograms.
The Zephyr device also is the first pacemaker that can, in about 90 seconds, tell physicians which device timing settings are optimal for each patient's needs, via the company's QuickOpt Timing Cycle Optimization feature.

'The enhanced sensing capability of the OptiSense lead promotes pacing that more closely mimics the natural workings of the heart', said Joseph H McCullough, president of St Jude Medical's International Division.

'Both the OptiSense lead and Zephyr pacemaker represent St Jude Medical's commitment to providing physicians with innovative systems that provide optimal therapy for their patients'.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo